The PE Ratio as of November 2024 (TTM) for Cell Source, Inc. (CLCS) is -3.58

According to Cell Source, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.58. This represents a change of 58.75% compared to the average of -2.26 of the last 4 quarters.

Cell Source, Inc. (CLCS) Historical PE Ratio (quarterly & annually)

How has CLCS PE Ratio performed in the past?

The mean historical PE Ratio of Cell Source, Inc. over the last ten years is -7.32. The current -3.58 PE Ratio has changed 4.79% with respect to the historical average. Over the past ten years (40 quarters), CLCS's PE Ratio was at its highest in in the December 2016 quarter at 2.17. The PE Ratio was at its lowest in in the June 2018 quarter at -15.95.

Cell Source, Inc. (CLCS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Cell Source, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cell Source, Inc. (CLCS) Average PE Ratio

How has CLCS PE Ratio performed in the past?

The current PE Ratio of Cell Source, Inc. (CLCS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Cell Source, Inc. (CLCS) PE Ratio vs. Peers

How is CLCS’s PE Ratio compared to its peers?

Cell Source, Inc.’s PE Ratio is less than Emmaus Life Sciences, Inc. (-0.50), less than Adhera Therapeutics, Inc. (-0.00), less than PolarityTE, Inc. (0.16), greater than ZIVO Bioscience, Inc. (-5.20), less than Pasithea Therapeutics Corp. (-0.00), greater than Nutriband Inc. (-7.34), less than MediciNova, Inc. (-0.04), less than Eliem Therapeutics, Inc. (-2.42), less than Panbela Therapeutics, Inc. (-0.06), less than Virpax Pharmaceuticals, Inc. (-0.20), less than Revelation Biosciences, Inc. (-0.13), less than Biodexa Pharmaceuticals Plc (-0.18), greater than Praxis Precision Medicines, Inc. (-9.32), less than Cardio Diagnostics Holdings, Inc. (-0.79), greater than Sigilon Therapeutics, Inc. (-16.76), less than Sonnet BioTherapeutics Holdings, Inc. (-1.88), less than ZyVersa Therapeutics, Inc. (-0.00), greater than X4 Pharmaceuticals, Inc. (-4.05), less than eFFECTOR Therapeutics, Inc. (-0.00), greater than Landos Biopharma, Inc. (-5.74), less than Apexigen, Inc. (-0.24), less than Navidea Biopharmaceuticals, Inc. (0.03), less than Angion Biomedica Corp. (-0.46),

Build a custom stock screener for Cell Source, Inc. (CLCS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cell Source, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cell Source, Inc. (CLCS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cell Source, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.